Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children

被引:9
|
作者
Pensieroso, Simone [1 ]
Romiti, Maria Luisa
Palma, Paolo
Castelli-Gattinara, Guido
Bernardi, Stefania
Freda, Elio
Rossi, Paolo
Cancrini, Caterina
机构
[1] Univ Roma Tor Vergata, Dept Publ Hlth, Chair Pediat, Rome, Italy
[2] Childrens Hosp Bambino Gesu, Div Immunol & Infect Dis, Rome, Italy
关键词
D O I
10.1097/01.aids.0000244211.33876.6f
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To evaluate the effects of switching from successful long-term protease inhibitor (PI)-based HAART to a three nucleoside reverse transcriptase inhibitor PI-sparing regimen, viral load quantification, HIV-specific lymphoproliferative assay and T-cell receptor (TCR) spectratyping were performed during 96 weeks of simplification follow-up in 19 HIV-infected children. Our data showed that simplification of therapeutic strategies acts positively on immune competence in HIV paediatric patients. Our children maintained viral suppression, increased lymphoproliferative responses and normalized TCRBV repertoire on the CD8 subset.
引用
收藏
页码:1893 / 1896
页数:4
相关论文
共 50 条
  • [1] Protease inhibitor-sparing regimen suppresses HIV
    不详
    [J]. AIDS PATIENT CARE AND STDS, 1998, 12 (12) : 940 - 940
  • [2] Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome
    Gianotti, N
    Soria, A
    Galli, L
    Giudici, B
    Fusetti, G
    Lazzarin, A
    Boeri, E
    Castagna, A
    [J]. AIDS, 2004, 18 (05) : 821 - 823
  • [3] Protease inhibitor therapy in HIV-infected children
    Feingold, AR
    Rutstein, RM
    Meislich, D
    Brown, T
    Rudy, BJ
    [J]. AIDS PATIENT CARE AND STDS, 2000, 14 (11) : 589 - 593
  • [4] Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients
    Asztalos, BF
    Schaefer, EJ
    Horvath, KV
    Cox, CE
    Skinner, S
    Gerrior, J
    Gorbach, SL
    Wanke, C
    [J]. ATHEROSCLEROSIS, 2006, 184 (01) : 72 - 77
  • [5] Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience
    Nozza, Silvia
    Galli, Laura
    Visco, Francesca
    Soria, Alessandro
    Canducci, Filippo
    Salpietro, Stefania
    Gianotti, Nicola
    Bigoloni, Alba
    Della Torre, Liviana
    Tambussi, Giuseppe
    Lazzarin, Adriano
    Castagna, Antonella
    [J]. AIDS, 2010, 24 (06) : 924 - 928
  • [6] Evaluation of Lipid Profile and Intima Media Thickness in Antiretroviral-Experienced HIV-Infected Patients Treated with Protease Inhibitor-Based Regimens versus Protease Inhibitor-Sparing Regimens
    Martini, Salvatore
    Pisaturo, Mariantonietta
    Russo, Antonio
    Palamone, Maria Grazia
    Russo, Maria Teresa
    Zollo, Verdiana
    Maggi, Paolo
    Coppola, Nicola
    [J]. PATHOGENS, 2023, 12 (07):
  • [7] Weight gain associated with protease inhibitor therapy in HIV-infected patients
    Stricker, RB
    Goldberg, B
    [J]. RESEARCH IN VIROLOGY, 1998, 149 (02): : 123 - 126
  • [8] Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study
    Masia, Mar
    Martinez, Esteban
    Padilla, Sergio
    Gatell, Jose M.
    Gutierrez, Felix
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (02) : 409 - 413
  • [9] PLASMA PROTEASE INHIBITOR CONCENTRATIONS AND FASTING LIPID PROFILES IN HIV-INFECTED CHILDREN
    Rakhmanina, N.
    Rongen, Avan
    van den Anker, J.
    Soldin, S.
    Williams, L.
    Neely, M.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1078 - 1078
  • [10] Protease inhibitor-associated hypertriglyceridemia and diabetes mellitus in HIV-infected patients
    Knobel, H
    Goday, A
    Grau, S
    [J]. MEDICINA CLINICA, 1998, 111 (15): : 599 - 599